XTalks

OCTOBER 16, 2024

Hympavzi’s approval, with its innovative approach to balancing clotting, could offer a modern solution that adds to the global effort to reduce the risk of thrombosis. This is Pfizer’s second FDA-approved treatment for a rare genetic blood disorder this year.

FDA Approval 98

FDA Approval Trials Clinical Trials Clinical Trials 98

XTalks

MARCH 25, 2021

Xtalks is proud to announce the launch of the Xtalks Life Science podcast. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Fresh Conversations About Life Science Topics. She focuses on news relating to the food industry and writes blogs on recruitment and HR in the life sciences.

Life Science 105

Life Science HR Clinical Trials Clinical Trials 105

XTalks

JANUARY 3, 2024

Wainua is the only FDA-approved drug for the treatment of ATTRv-PN that can be self-administered via an auto-injector. Approval of Wainua represents a meaningful advancement in treatment, one that gives those who are living with transthyretin-mediated amyloid polyneuropathy help managing the disease,” said Michael J.

FDA Approval 102

FDA Approval Protein RNA Clinical Trials 102

XTalks

JANUARY 2, 2024

For instance, Vyjuvek , the first FDA-approved gene therapy for DEB, is priced at $24,250 per vial. a biotech company specializing in the development and commercialization of genetic medicines for rare diseases, announced FDA approval for Vyjuvek for the treatment of DEB.

FDA Approval 104

FDA Approval Gene Therapy Gene Trials 104

XTalks

APRIL 3, 2024

Related: Novartis’ Fabhalta Gets FDA Approval for Rare Complement Blood Disorder The FDA’s green light for Voydeya comes three months after the Japanese Ministry of Health, Labour and Welfare (JHLW) became the first regulator in the world to back the therapy. AstraZeneca is also venturing into cell therapy and genetic medicine.

FDA Approval 87

FDA Approval Sales Trials Development 87

XTalks

JUNE 20, 2022

Amvuttra’s FDA approval is based on positive data from the global, randomized, open-label, multicenter HELIOS-A Phase III study from a period of nine months. The condition has very limited treatment options. Amvuttra is administered via subcutaneous injection four times a year or once every three months (quarterly).

FDA Approval 98

FDA Approval Protein Genetics RNA 98

XTalks

DECEMBER 29, 2022

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 97

Life Science RNA Vaccination Vaccine 97

XTalks

JANUARY 26, 2023

This is the fourth US FDA approval that BeiGene has received for Brukinsa since 2019. Diagnosis is confirmed by a differential complete blood count and genetic testing. Treatment selection is determined by age, disease severity, comorbidities and the presence or absence of certain genetic mutations.

FDA Approval 89

FDA Approval Life Science Clinical Trials Clinical Trials 89

XTalks

SEPTEMBER 12, 2022

After approvals in Japan and Europe, Sanofi’s Xenpozyme has secured one from the US Food and Drug Administration (FDA) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. Patients in the trial received Xenpozyme or placebo for 52 weeks.

FDA Approval 97

FDA Approval Genetics Trials Gene 97

XTalks

DECEMBER 13, 2023

This approval also marks bluebird’s third ex vivo gene therapy approved by the FDA for a rare genetic disease and second FDA approval for an inherited hemoglobin disorder, cementing our position as a gene therapy leader.”

Gene Therapy 96

Gene Therapy Gene FDA Approval In-Vivo 96

XTalks

NOVEMBER 10, 2023

Today, we are proud to further support the rare disease community by delivering Adzynma as the first FDA-approved therapeutic option for people with cTTP.” In 2022, the FDA approved 20 orphan drugs out of the 37 novel drugs approved by the FDA’s Center for Drug Evaluation and Research (CDER).

FDA Approval 59

FDA Approval Gene Therapy Gene Clinical Trials 59

XTalks

MARCH 10, 2023

This US Food and Drug Administration (FDA)-approved drug was also awarded a rare pediatric disease priority review voucher. In the MOXIe Part 2 trial, 82 patients with Friedreich’s ataxia (as confirmed by genetic testing) were randomized 1:1 to receive either 150 mg omaveloxolone or placebo.

FDA Approval 52

FDA Approval Engineer Clinical Trials Clinical Trials 52

XTalks

APRIL 11, 2024

After backing from the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) last month, Johnson and Johnson (J&J) and Bristol Myers Squibb (BMS) scored FDA approvals for the use of their B-cell maturation antigen (BCMA)-targeting CAR T-cell therapies as earlier line treatment options for multiple myeloma.

FDA Approval 52

FDA Approval Manufacturing Trials Clinical Trials 52

XTalks

NOVEMBER 26, 2024

BridgeBio has been highly active in the genetic diseases space. Its investigational therapy infigratinib recently received Breakthrough Therapy designation, becoming the first-ever potential treatment for achondroplasia — a genetic condition affecting bone growth — to achieve this milestone.

Genetic Disease 101

Genetic Disease Genetics Protein Clinical Development 101

XTalks

DECEMBER 3, 2024

The FDA has also approved innovative solutions like the iLet Bionic Pancreas , an artificial pancreas system that uses advanced algorithms to automate insulin delivery. The first genetically engineered human insulin , Humulin , was introduced in 1982. percent to the company’s total net sales.

52

52

XTalks

JANUARY 27, 2023

The website brings awareness for facial angiofibroma, an aspect of the rare genetic disease tuberous sclerosis complex (TSC). Hyftor became the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis.

Life Science 97

Life Science Genetic Disease FDA Approval Marketing 97

XTalks

NOVEMBER 7, 2024

Related: Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease Elevidys: Precision Therapy for Duchenne Muscular Dystrophy Moving from genetic blood disorders to muscular dystrophy, Elevidys (delandistrogene moxeparvovec-rokl) offers new possibilities for patients.

Gene Therapy 102

Gene Therapy Gene Editing Gene FDA Approval 102

XTalks

SEPTEMBER 18, 2024

The US Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt) , a treatment for patients with mild cognitive impairment or mild dementia caused by Alzheimer’s. To mitigate this, genetic testing for APOE4 is recommended before treatment.

FDA Approval 90

FDA Approval Clinical Trials Clinical Trials Trials 90

World of DTC Marketing

JANUARY 24, 2022

A group of early-stage life science investors and biotech CEOs joined together with a prominent patient advocate to speak out against H.R.3, The panel was hosted by the life sciences venture capital coalition Incubate and held at the National Press Club. Only about $2.2 3, known as the Lower Drug Costs Now Act.

Life Science 225

Life Science Drugs Development Genetic Disease 225

XTalks

MAY 31, 2022

The precise cause of psoriasis is unknown, but risk factors include genetics and a family history of the condition, heavy alcohol consumption, stress, smoking and dry or cold weather. It has been estimated that around eight million people in the US and 125 million people in the world have been affected by psoriasis.

FDA Approval 97

FDA Approval Clinical Trials Clinical Trials Trials 97

XTalks

JUNE 29, 2022

The new FDA approval gives Breyanzi (lisocabtagene maraleucel) the broadest patient eligibility of any CAR T-cell therapy in relapsed or refractory LBCL. Treatment with Breyanzi is a tailored method of treatment which involves the genetic reprogramming of T cells. Product logo and product image courtesy of Bristol Myers Squibb.

FDA Approval 52

FDA Approval Gene Therapy Antibody Gene 52

XTalks

MARCH 21, 2023

It is estimated that Rett syndrome affects 6,000 to 9,000 patients in the US, with a diagnosed population of approximately 4,500 patients, according to a press release from Acadia announcing Daybue’s approval. However, in animal studies, trofinetide has been shown to increase dendritic branching and synaptic plasticity signals.

FDA Approval 79

FDA Approval Gene Therapy Gene Genetics 79

XTalks

SEPTEMBER 6, 2024

As the co-founder of Blueprint Genetics, a proud member of the Quest Diagnostics family, I’ve witnessed firsthand the complexities and nuances involved in rare disease diagnostics and the development of orphan drugs. With over 7,000 rare diseases identified to date, a significant proportion lacks FDA-approved treatments.

Genetics 52

Genetics Drugs Development FDA Approval 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. SK Life Science is a subsidiary of SK, a South Korean holding company.

Research 264

Research Gene Gene Therapy Genomics 264

XTalks

AUGUST 9, 2024

Wolfram syndrome is a rare, genetic neurodegenerative disorder characterized by childhood-onset diabetes, optic atrophy and deafness. It often leads to severe complications, including neurodegeneration, and has a significantly reduced life expectancy.

Drugs 52

Drugs Life Science FDA Approval Genetics 52

XTalks

JULY 29, 2024

This blog will discuss new US Food and Drug Administration(FDA)-approved treatments, promising clinical trials and the latest advancements in lung cancer research, providing hope for better patient outcomes. New FDA-approved therapies have been found to be more effective and have fewer side effects than traditional chemotherapy.

Research 59

Research Clinical Trials Clinical Trials FDA Approval 59

XTalks

MAY 17, 2023

In 2022, the FDA approved four new gene therapies, and more than a handful are looking to get approval this year for diseases including Duchenne muscular dystrophy (DMD), sickle cell disease (SCD) and hemophilia A. Of the more than 10,000 rare diseases, more than 80 percent are caused by genetic defects.

Gene Therapy 91

Gene Therapy Clinical Trials Clinical Trials Gene 91

XTalks

FEBRUARY 27, 2023

Chiesi Global Rare Diseases recently announced in a press release that Lamzede (velmanase alfa-tycv) received US Food and Drug Administration (FDA) approval for the treatment of non-neurological manifestations of alpha-mannosidosis in both adult and pediatric patients.

FDA Approval 52

FDA Approval Life Science Containment Genetics 52

XTalks

MAY 15, 2023

Chiesi Global Rare Diseases in collaboration with Protalix BioTherapeutics announced the US Food and Drug Administration (FDA) approval of their new medication Elfabrio (pegunigalsidase alfa-iwxj) for the treatment of Fabry disease. Genetic confirmatory testing is then conducted to identify the specific mutations in the GLA gene.

FDA Approval 95

FDA Approval Gene Genetics Clinical Trials 95

XTalks

NOVEMBER 27, 2023

Amicus Therapeutics has recently received approval from the US Food and Drug Administration (FDA) for its drugs Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) for adults living with late-onset Pompe disease (LOPD) who are not improving on their current enzyme replacement therapy (ERT).

FDA Approval 96

FDA Approval Clinical Trials Clinical Trials Trials 96

XTalks

MAY 26, 2023

Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical gene therapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable gene therapy.

Gene Therapy 90

Gene Therapy Gene FDA Approval Dermatology 90

XTalks

SEPTEMBER 25, 2024

In a significant regulatory milestone, the US Food and Drug Administration (FDA) approved Aqneursa (levacetylleucine) for treating neurological symptoms associated with Niemann-Pick disease type C (NPC). NPC, caused by mutations in the NPC1 or NPC2 gene, typically shortens life expectancy to around 13 years.

FDA Approval 52

FDA Approval Drugs Protein Gene 52

XTalks

JUNE 5, 2023

The genetic material of RSV (respiratory syncytial virus) encodes 11 proteins. Today’s FDA approval of Abrysvo recognizes significant scientific progress, and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease,” said Edward E.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

XTalks

OCTOBER 9, 2024

Ataxia is a rare genetic condition that results from damage to the cerebellum or spinal cord. This includes both inherited and acquired types of the disorder, with Friedreich’s ataxia being the most common genetic form. In the US, it is estimated that around 150,000 people are living with some form of ataxia.

Genetics 52

Genetics FDA Approval Research Trials 52

XTalks

NOVEMBER 30, 2023

New FDA-Approved Treatments For HIV HIV treatment involves the administration of combined antiretroviral therapy (ART) to effectively suppress the viral load, maintain or enhance immune function and reduce the risk of opportunistic infections and cancers commonly associated with HIV. aiming to end the HIV epidemic by 2030.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

XTalks

MAY 12, 2023

Rett syndrome is a rare genetic disorder that predominantly affects girls and leads to severe physical and cognitive impairments. In March, the US Food and Drug Administration (FDA) approved Daybue (trofinetide) , the first and only treatment for Rett syndrome. It affects around one in 10,000 girls born each year.

FDA Approval 89

FDA Approval Genetics Trials Drugs 89